证券代码：301166 证券简称：优宁维 公告编号：2025-043 上海优宁维生物科技股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东持股情况的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 三、备查文件 1、中国证券登记结算有限责任公司深圳分公司出具的股东名册。 特此公告。 上海优宁维生物科技股份有限公司董事会 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的规定， 现将公司 2024 年度股东大会股权登记日（即 2025 年 5 月 6 日）登记在册的前十 名股东和前十名无限售条件股东的名称、持股数量和持股比例情况公告如下： 注：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股数量。 二、公司前十名无限售条件股东持股情况 序号 股东名称 持股数量（股） 占公司总股本的比例（%） 1 冷兆武 28,674,000 33.09% 2 许晓萍 8,980,200 10.36% 3 上海创业接力泰礼创业投资中心（有限合伙） 5,075,688 5.86% 4 上海阳卓投资合伙企业（有限合伙） 4,779,000 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-042 上海优宁维生物科技股份有限公司 关于使用闲置募集资金及自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个 月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分别 于 2025 年 2 月 19 日和 2025 年 3 月 8 日刊载于巨潮资讯网（www.cninfo.com.cn） 的 ...

Financial Performance - In 2024, the company's operating revenue decreased by 8.82% year-on-year, while net profit attributable to shareholders dropped by 74.83%, with a non-recurring net profit of -15.11 million yuan [2] - The decline in revenue is attributed to changes in downstream market demand, intensified competition in the domestic life sciences service market, and increased operational costs due to the completion of the self-owned brand product production base project [2][3] Brand Performance - Revenue from self-owned brands (Absin, LabEx, etc.) grew by nearly 30% year-on-year, while revenue from third-party brands declined significantly due to market competition [3][6] - The self-owned brand business, which accounts for over 90% of total revenue, faced substantial impacts from the downturn in third-party brand sales [3] Strategic Initiatives - The company aims to enhance its core competitiveness through a dual strategy of internal growth and external expansion, focusing on product pipeline enhancement, supply chain investment, and information technology [4] - Plans to accelerate the overseas expansion of self-owned brands, including the establishment of a subsidiary in Singapore and participation in online and offline promotional activities [4][5] Cost Management - The company continues to invest in marketing, product expansion, supply chain, and R&D to maintain service capabilities and improve the revenue share of self-owned products [2][4] - Direct sales decreased by 12.74%, prompting a shift towards distribution channels to reach price-sensitive customers [4] R&D and Innovation - As of the end of 2024, the company’s antibody R&D center in Hangzhou has developed over 2,900 products, while the protein R&D center in Nanjing has developed over 1,700 products [5] - The company is committed to leveraging information technology to enhance operational efficiency and customer service [7] Compliance and Safety - The company has established safety management systems and protocols to ensure compliance and safety in hazardous waste management [7]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0700 | 0.0600 | -216.67 | 0.2000 | | 每股净资产（元） | 23.71 | 24.48 | -3.15 | 25.1 | | 每股公积金(元) | 19.79 | 19.79 | 0 | 19.83 | | 每股未分配利润(元) | 2.71 | 3.24 | -16.36 | 3.87 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.16 | 2.72 | -20.59 | 2.74 | | 净利润(亿元) | -0.06 | 0.05 | -220 | 0.18 | | 净资产收益率(%) | -0.45 | 0.02 | -2350 | 0.49 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 1029.72万股，累计占流通股比： 2 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-041 上海优宁维生物科技股份有限公司 关于 2025 年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"）根据《深圳证券交易 所创业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号 —业务办理第一章信息披露：第二节定期报告披露相关事宜》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及公司相关会计政 策的规定，基于谨慎性原则，为了真实准确地反映公司的资产和财务状况，对合 并报表范围内截至 2025 年 3 月 31 日的各类应收款项、固定资产等进行了全面 清查。对各项资产减值的可能性进行了充分的评估和分析，判断存在可能发生减 值的迹象，确定了需计提的减值准备。现将有关情况公告如下： 一、本次计提资产减值准备情况概述 本次计提资产减值准备计入的报告期间为 2025 年 1 月 1 日至 2025 年 3 月 31 日。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥216,368,460, a decrease of 20.34% compared to ¥271,631,039.66 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥6,208,677.82, representing a decline of 219.34% from a profit of ¥5,202,522.95 in the previous year[5] - Total operating revenue decreased to ¥216,368,460.00 from ¥271,631,039.66, representing a decline of approximately 20.4% year-over-year[19] - Net profit for the period was a loss of ¥6,208,677.82, compared to a profit of ¥5,202,522.95 in the previous period, indicating a significant decline[20] - The company reported a gross profit margin of approximately -6.5% for the current period, compared to a positive margin in the previous period[19] - Basic and diluted earnings per share were both -¥0.07, down from ¥0.06 in the previous period, reflecting the company's financial challenges[20] Cash Flow and Investments - The net cash flow from operating activities improved to -¥23,026,807.37, a 60.97% increase compared to -¥58,999,143.47 in the same period last year[5] - Operating cash flow for the current period is -23,026,807.37, an improvement from -58,999,143.47 in the previous period, indicating a reduction in cash outflow[21] - Total cash inflow from investment activities decreased to 478,295,415.16 from 862,538,137.50, reflecting a significant decline in investment recovery[21] - Net cash flow from investment activities is -399,837,948.09, worsening from -57,230,490.63 in the previous period, highlighting increased cash outflow for investments[21] - Cash and cash equivalents at the end of the period stand at 401,022,528.97, up from 295,240,832.24 in the previous period[22] - The company reported a total cash outflow from financing activities of 7,930,876.13, compared to 3,069,512.87 in the previous period, indicating increased cash payments related to financing[22] - The net increase in cash and cash equivalents for the current period is -430,809,072.97, a significant decline from -119,286,312.09 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,247,681,984.83, down 2.67% from ¥2,309,420,442.59 at the end of the previous year[5] - The company's total assets decreased to ¥2,247,681,984.83 from ¥2,309,420,442.59, a reduction of approximately 2.7%[18] - Total liabilities decreased to ¥192,699,789.46 from ¥241,515,885.28, a decline of about 20.2% year-over-year[18] - The company’s total equity decreased to ¥2,054,982,195.37 from ¥2,067,904,557.31, a decline of about 0.6% year-over-year[18] Shareholder Information - The company had a total of 10,851 common shareholders at the end of the reporting period[10] - The top two shareholders held 43.45% of the company's shares, with the largest shareholder owning 33.09%[11] - The company repurchased a total of 927,600 shares, accounting for 1.07% of the total share capital, with a total expenditure of RMB 25,987,076[14] - The maximum repurchase price was RMB 31 per share, while the minimum was RMB 24.98 per share[14] - The company plans to use between RMB 15 million and RMB 30 million of its own funds for further share repurchases, with a maximum price of RMB 44 per share[14] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[13] - The company has not disclosed any information regarding preferred shareholders or restricted shares[14] Financial Performance Metrics - The weighted average return on net assets was -0.45%, a decrease of 0.47% from 0.02% in the previous year[5] - Research and development expenses were ¥14,595,809.76, slightly down from ¥14,643,002.03, indicating stable investment in innovation[20] - Deferred income tax assets increased to ¥84,119,128.98 from ¥76,299,993.81, suggesting potential future tax benefits[18] Other Information - The company experienced a 90.39% increase in taxes and surcharges, amounting to ¥705,653.94, primarily due to an increase in property tax[9] - Financial expenses decreased by 75.62% to -¥848,293.79, attributed to currency exchange rate fluctuations[9] - The company has not yet adopted the new accounting standards as of the first quarter report[23] - The first quarter report has not been audited, which may affect the reliability of the financial data presented[23]

Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. introduced its basic situation and 2024 operational performance during the investor relations activity [2]. Impact of Tariff Policies - The impact of increased tariffs on exports is minimal due to the low export ratio; however, it affects imports from the U.S. and promotes the development of the company's own brand [2]. Business Strategy for 2024 - The company will focus on a one-stop platform strategy and antibody strategy, increasing investment in R&D, promoting its own brand, and enhancing operational efficiency through information technology [2]. R&D Investment - In 2024, R&D investment reached CNY 62.77 million, a year-on-year increase of 7.10%, with R&D expenditure accounting for 5.62% of revenue [3]. Product Development - The company has significantly increased its product offerings, with over 2,900 products developed at the Nanjing Protein R&D Center and a nearly 30% year-on-year growth in revenue from its own brand in 2024 [3]. Share Buyback Program - In 2024, the company initiated a share buyback plan, utilizing CNY 25,987,076 to repurchase shares for employee stock ownership plans, aiming to enhance investor confidence and promote sustainable development [3]. Future Market Strategy - The company plans to enrich its product system and enhance both third-party and self-owned brand offerings, leveraging 20 years of experience in life sciences to provide comprehensive solutions to meet diverse customer needs [3].

其中以集中竞价交易方式减持在任意连续90日内，减持股份的总数不超过公司扣除回购专户股份后总股 本的1%；以大宗交易方式减持在任意连续90日内，减持股份的总数不得超过公司扣除回购专户股份后 总股本的2%。 上市次日，优宁维盘中创下股价最高点136元，此后股价震荡下跌。目前该股处于破发状态。 优宁维首次公开发行股票募集资金总额为18.65亿元，扣除发行费用后，募集资金净额为15.96亿元。优 宁维最终募集资金净额比原计划多13.12亿元。优宁维于2021年12月23日披露的招股说明书显示，公司 拟募集资金2.83亿元，计划分别用于线上营销网络与信息化建设项目、线下营销及服务网络升级项目、 研发中心建设项目、补充流动资金项目。 中国经济网北京4月23日讯优宁维（301166）(301166.SZ)昨日晚间披露公告称，股东上海创业接力泰礼 创业投资中心(有限合伙)(以下简称"泰礼投资")及其一致行动人上海泰礼创业投资管理有限公司-上海含 泰创业投资合伙企业(有限合伙)(以下简称"含泰投资")计划自减持计划公告披露之日起15个交易日后的3 个月内通过集中竞价或大宗交易的方式合计减持不超过2,572,172股，减持比例不 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、本次会计政策变更对公司的影响 本次会计政策变更是公司根据财政部修订的最新会计准则进行的相应变更，符合相关法律法规的规定和 公司实际情况，不会对公司财务状况、经营成果和现金流量产生重大影响，不存在损害公司及全体股东 利益的情形。 三、董事会对本次会计政策变更合理性的说明 经审核，董事会认为：本次会计政策变更是公司根据财政部发布的《企业会计准则解释第18号》（财会 〔2024〕24号）的要求进行的相应变更，符合相关法律法规的规定和公司实际情况，不存在损害公司和 全体股东利益的情形。因此，董事会同意本次会计政策的变更。 四、监事会关于会计政策变更的意见 经审核，监事会认为：本次会计政策变更是根据财政部相关文件要求进行的合理变更，符合《企业会计 准则》及相关规定，符合公司实际情况，能够客观、公允地反映公司的财务状况和经营成果，本次会计 政策变更的决策程序符合有关法律、法规和《公司章程》的规定，不存在损害公司和中小股东利益的情 形。 五、备查文件 1、公司第四届董事会第五次会议决议； 2、公司第四届监事会第五次会议决议。 特此公告。 上海优宁维生物科技股份有限公司董 ...

Core Viewpoint - The company, Shanghai Univey Biotech Co., Ltd., has conducted a self-evaluation of its internal control effectiveness as of December 31, 2024, and found no significant defects in both financial and non-financial reporting internal controls [3][34]. Internal Control Evaluation Conclusion - The board of directors concluded that the company has maintained effective internal controls over financial reporting in all significant aspects [3]. - No significant defects were identified in non-financial reporting internal controls as of the evaluation report date [3]. Internal Control Evaluation Work Situation Evaluation Scope - The evaluation scope was determined based on a risk-oriented principle, covering the company and its important subsidiaries, focusing on five main elements of internal control: internal environment, risk assessment, control activities, information and communication, and internal supervision [4]. Internal Environment - The company has established a governance structure in compliance with relevant laws and regulations, ensuring effective division of responsibilities and checks and balances [5][6]. - Internal audit functions are managed by the corporate management department, which oversees both internal and external audits [8]. Risk Assessment - The company has identified various internal risk factors, including management integrity, employee competence, and operational safety, and has established a risk management framework to address these risks [10][11]. Control Activities - The company has implemented control policies and procedures, including authorization management, segregation of incompatible duties, accounting system controls, asset protection controls, and independent auditing controls [13][14]. Information and Communication Control - A robust information and communication system has been established, ensuring effective information flow across departments and timely financial reporting [15]. Internal Control Defects Recognition and Rectification - The company has not identified any significant or important defects in internal controls during the reporting period [34]. Company Overview Main Business - The company provides life science reagents and related instruments, consumables, and comprehensive technical services, focusing on antibody-based products [38]. - It has integrated over 60 well-known brands and offers more than 9.7 million SKUs, covering various research areas in life sciences [38][41]. Operating Model - The company employs a dual procurement model, including stock procurement and sales-driven procurement, to meet the diverse needs of its clients [42]. - Sales are conducted through a nationwide network of subsidiaries and offices, complemented by an online platform [43][44]. Production Model - The company primarily acts as an agent for third-party brand products while also engaging in self-production through its subsidiaries [48][49]. Research and Development - The company focuses on innovative research and development based on customer needs, with dedicated teams for product and technology development [51][53].